Semaglutide Dosing for Weight Loss
For weight loss in adults with BMI ≥27 kg/m² with comorbidities or ≥30 kg/m² without comorbidities, start semaglutide at 0.25 mg subcutaneously once weekly for 4 weeks, then escalate to 0.5 mg weekly for 4 weeks, then 1.0 mg weekly for 4 weeks, then 1.7 mg weekly for 4 weeks, reaching the target maintenance dose of 2.4 mg weekly by week 16. 1
Dose Titration Schedule
The gradual dose escalation is critical to minimize gastrointestinal adverse effects, particularly nausea and vomiting:
- Weeks 1-4: 0.25 mg once weekly (initiation dose, not therapeutic)
- Weeks 5-8: 0.5 mg once weekly
- Weeks 9-12: 1.0 mg once weekly
- Weeks 13-16: 1.7 mg once weekly
- Week 17 onward: 2.4 mg once weekly (maintenance dose)
This 16-week titration schedule is the FDA-approved regimen and is explicitly recommended by the 2022 AGA guidelines to reduce the 40% incidence of nausea and 16% incidence of vomiting seen with this medication 1, 2.
Administration Details
- Frequency: Once weekly on the same day each week
- Timing: Any time of day, with or without meals
- Route: Subcutaneous injection into abdomen, thigh, or upper arm
- Site rotation: Use different injection sites each week within the same body region 2
Efficacy at Target Dose
At the 2.4 mg weekly maintenance dose, semaglutide produces substantial weight loss:
- Mean weight loss of 14.9-16.0% at 68 weeks in patients without diabetes 3
- 64.9% of patients achieve ≥10% total body weight loss 1
- 46.1% achieve ≥15% total body weight loss 1
This represents superior efficacy compared to other anti-obesity medications and may be prioritized as first-line pharmacotherapy 1.
Dose Adjustments and Missed Doses
If doses are missed:
- ≤5 days late: Administer as soon as possible, then resume regular schedule
- >5 days late: Skip the missed dose and give next dose on regularly scheduled day 2
If 2 consecutive doses are missed: Resume at the same dose if previously well-tolerated; otherwise consider lowering the dose 1
If ≥3 consecutive doses are missed: Restart the full titration schedule from 0.25 mg 1
Submaximal dosing: Some patients achieve adequate response at doses <2.4 mg (e.g., 1.0 mg or 1.7 mg weekly). If weight loss goals are met at a lower dose with good tolerability, continuing that dose long-term is acceptable 1. Real-world data shows 40% of patients remain on ≤1.0 mg weekly at 12 months 4.
Critical Safety Considerations
Absolute contraindications (must screen before prescribing):
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to semaglutide 1, 2
Common adverse effects:
- Gastrointestinal symptoms (nausea 40%, vomiting 16%, diarrhea, constipation, abdominal pain) are dose-dependent and typically improve with gradual titration 1
- Risk of pancreatitis, gallbladder disease (cholelithiasis, cholecystitis) 1
Drug interactions:
- Do NOT combine with other GLP-1 receptor agonists or DPP-4 inhibitors
- May delay gastric emptying and affect absorption of oral medications requiring rapid onset
- If used with insulin or sulfonylureas, reduce doses of these agents to prevent hypoglycemia 1
Duration of Treatment
Semaglutide must be used lifelong for sustained weight loss. Weight regain occurs rapidly after discontinuation—patients regained 11.6% of lost weight within 52 weeks after stopping treatment 3. In real-world practice, 38% of patients discontinue by 12 months, highlighting the importance of setting appropriate expectations 4.
Lifestyle Intervention Requirement
Semaglutide is FDA-approved only as an adjunct to diet and exercise, not as monotherapy. Patients should follow:
- Reduced-calorie diet (typically 500 kcal/day deficit)
- ≥150 minutes per week of physical activity 3, 1
The medication's efficacy is optimized when combined with these lifestyle modifications 3.
Cardiovascular Benefits
Beyond weight loss, semaglutide 2.4 mg reduces major adverse cardiovascular events (cardiovascular death, non-fatal MI, non-fatal stroke) by 20% in patients with established cardiovascular disease and BMI ≥27 kg/m² (HR 0.80,95% CI 0.72-0.90) 3. This provides additional mortality benefit beyond weight reduction alone.